An increasing number of consortia and organizational alliances have coalesced around specific problems and issues of public health importance. By pooling and leveraging funding and other resources, such partnerships seek to address complex health problems collectively and to invite widespread public- and private-sector participation. NIAID and other National Institutes of Health (NIH) Institutes participate in various consortia, including the following:
- Global HIV Vaccine Enterprise
- Alliance for Microbicide Development
- Partnership for AIDS Vaccine Evaluation (PAVE)
- Multilateral Initiative on Malaria (MIM)
NIAID was a founding member of MIM, which emphasizes strengthening the research capacity of African scientists working in malaria-endemic regions. PAVE is an example of a voluntary consortium of U.S. government agencies—U.S. Agency for International Development, Centers for Disease Control and Prevention, U.S. Military HIV Research Program, and NIH (including NIAID and the Office of AIDS Research)—and other organizations involved in HIV vaccine research, including the NIAID-supported HIV Vaccine Trials Network.
Several international consortia have resulted in landmark scientific achievements. For example, in 1999, NIAID joined the Anopheles gambiae Genome Consortium to accelerate sequencing of the genes of the mosquito species most responsible for transmitting malaria to humans. NIAID and the French government contributed funds to this venture. Other partners included private companies such as Genoscope and Celera Genomics, the World Health Organization, research institutes in Germany and Greece, the Institut Pasteur, The Institute for Genomic Research, and several universities.